AGENNIX

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

Phase 2

Suspended

Conditions: Severe Sepsis

Interventions: Drug: Talactoferrin alfa
Drug: Placebo

First Posted Date: 2011-01-11

Last Posted Date: 2012-02-03

Lead Sponsor: Agennix

Target Recruit Count: 1280

Registration Number: NCT01273779

Locations: 🇨🇦
Royal Jubilee Hospital, Victoria, British Columbia, Canada
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Methodist Research Institute, Indianapolis, Indiana, United States

and more 96 locations

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

Phase 1

Withdrawn

Conditions: Hematological Malignancies

First Posted Date: 2010-07-23

Last Posted Date: 2012-08-02

Lead Sponsor: Agennix

Registration Number: NCT01168882

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

Phase 1

Conditions: Nosocomial Infections

Interventions: Drug: Talactoferrin
Drug: Placebo

First Posted Date: 2009-03-03

Last Posted Date: 2012-03-15

Lead Sponsor: Agennix

Target Recruit Count: 120

Registration Number: NCT00854633

Locations: 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
University of Missouri Health Care, Columbia Regional Hospital, Columbia, Missouri, United States
🇺🇸
University of Louisville Hospital, Louisville, Kentucky, United States

and more 1 locations

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Phase 3

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Talactoferrin
Drug: Placebo

First Posted Date: 2008-06-30

Last Posted Date: 2012-03-15

Lead Sponsor: Agennix

Target Recruit Count: 1100

Registration Number: NCT00706862

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States

and more 3 locations

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Talactoferrin
Drug: Placebo

First Posted Date: 2008-06-30

Last Posted Date: 2012-08-21

Lead Sponsor: Agennix

Target Recruit Count: 742

Registration Number: NCT00707304

Locations: 🇮🇳
Kaushalya Medical Foundation Trust Hospital, Mumbai, Maharashtra, India
🇺🇸
Legacy Pharma Research, Bismarck, North Dakota, United States
🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

and more 183 locations

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Phase 2

Completed

Conditions: Severe Sepsis

Interventions: Drug: Placebo
Drug: Talactoferrin alfa

First Posted Date: 2008-03-07

Last Posted Date: 2011-08-23

Lead Sponsor: Agennix

Target Recruit Count: 190

Registration Number: NCT00630656

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
🇺🇸
University of Pittsburgh Medical Center Presbyterian Hospital, Pittsburgh, Pennsylvania, United States

and more 31 locations

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Phase 1

Terminated

Conditions: Prostate Cancer

First Posted Date: 2007-05-31

Last Posted Date: 2012-03-23

Lead Sponsor: Agennix

Registration Number: NCT00480623

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
UT Southwestern Medical Center at Dallas, Dallas, Texas, United States

and more 1 locations

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Oral Satraplatin

First Posted Date: 2007-03-22

Last Posted Date: 2012-08-17

Lead Sponsor: Agennix

Target Recruit Count: 344

Registration Number: NCT00450970

Locations: 🇺🇸
Mid-Ohio Oncology/Hematology, Columbus, Ohio, United States
🇺🇸
Lone Star Oncology Consultants, Austin, Texas, United States
🇺🇸
Virginia Oncology Associates, Newport News, Virginia, United States

and more 116 locations

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Erlotinib
Drug: Satraplatin

First Posted Date: 2006-08-31

Last Posted Date: 2012-08-07

Lead Sponsor: Agennix

Target Recruit Count: 100

Registration Number: NCT00370383

Locations: 🇺🇸
Highlands Oncology Group, Bentonville, Ohio, United States
🇺🇸
Signal Point Hematology/Oncology, Middleton, Ohio, United States
🇨🇦
Princess Margaret Hospital, Toronto, Canada

and more 13 locations

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Phase 1

Terminated

Conditions: Malignancies

First Posted Date: 2006-05-24

Last Posted Date: 2012-03-23

Lead Sponsor: Agennix

Target Recruit Count: 24

Registration Number: NCT00329329

Locations: 🇺🇸
Northwestern University Medical Center, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy